Understanding What Patients Want
At IHH, we believe in touching lives and making a difference for our patients and their loved ones.
Our commitment to our patients is that they will get better treatment, care and outcomes from our network than anywhere else. To keep our commitment, we uphold the highest standards of quality and safety in care, and deliver it with empathy.
From day-to-day healthcare to advanced specialised care, our people go the extra mile to ensure that our patients are in trusted hands.
Defining care from the perspective of our patients – that’s what our Value Driven Outcomes (VDO) initiative in Malaysia, Singapore, Turkey, Brunei and Hong Kong, is all about. By identifying and predicting the outcomes and costs of care, IHH provides accountability and transparency so patients are confident that they are receiving excellent value-for-money services.
VDO has led to changes in clinical practice and better outcomes. Doctors are aligned to a set of quality and functional outcomes. This allows us to drive potential interventions and improve treatment value to the patient.
For a start, four common high-volume and high-impact procedures have been selected for the initiative – Total Knee Replacement (TKR), colonoscopy, Anterior Cruciate Ligament Surgery (ACL) and Percutaneous Coronary Intervention (PCI).
Providing cost-effective and evidence-based treatment is our approach to upholding excellence in healthcare. We continue to invest in new medical technologies that make healthcare better, easier, faster and more affordable for our patients.
For example, we partner with innovative start-ups to sharpen our in-house precision medicine capabilities, enabling doctors and patients to make better informed decisions on how to manage diseases more efficiently and safely.
Come 2022, IHH will be the first private hospital in Southeast Asia to offer proton therapy treatment at its Mount Elizabeth Novena Hospital, Singapore. Our largest single investment in medical technology by far, proton therapy will revolutionise the way cancer is treated in this region with its unique dose deposition that enables the tumour to be targeted more effectively than other treatments.
Delivering care at the patient’s convenience is an ongoing pursuit that has accelerated in response to the global COVID-19 pandemic.
To provide patients around the world with safe and convenient healthcare services, IHH has rolled out telemedicine in our key markets of Malaysia, Singapore, Turkey, India, China and Hong Kong.
As a complement to our brick-and-mortar business, we have also launched mobile apps in multiple countries to enable our patients to make appointments, retrieve medical records and access other healthcare services and information, at their fingertips.
Building strategic partnerships to advance clinical excellence - our recent collaboration with Sharehereon Health has opened doors to high-quality refractory cancer care at Parkway Shanghai Hospital.
The Centre of Genomic Health aims to help individuals and their families uncover any possible genetic mutations linked to potential illnesses or health conditions, allowing them to take necessary steps early on.
IHH Malaysia is rolling out a ‘Ready For You’ campaign to train 1,000 individuals from key consumer-facing services in Cardiopulmonary Resuscitation (CPR) and use of Automated External Defibrillator (AED).
Introducing the new MyHealth360 Shop, an online shopping destination that offers a curated range of healthcare services in Singapore by IHH brands including Gleneagles, Mount Elizabeth and Parkway.
Mount Elizabeth Novena Hospital opened its highly anticipated Proton Therapy Centre on 10 May offering one of the most advanced forms of precision cancer treatments.